Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies

PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc., a genome editing company developing universal donor stem cells, today announced that they have entered into a collaboration and exclusive license agreement for the development of allogeneic T-cell therapies...

New York, 01/12/2015 (informazione.it - comunicati stampa - scienza e tecnologia)
Copyright GlobeNewswire


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire